Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy

We present a patient with autoimmune autonomic ganglionopathy (AAG) who had persistently positive ganglionic nicotinic acetylcholine receptor antibody levels despite immunosuppressive therapy. Rituximab-based therapy for an incidental lymphoma was associated with prolonged symptomatic and serologica...

Full description

Saved in:
Bibliographic Details
Published in:Clinical autonomic research 2015-08, Vol.25 (4), p.255-258
Main Authors: Gupta, Arjun, Harris, Samar, Vernino, Steven, Naina, Harris V.
Format: Article
Language:English
Subjects:
Autoimmune Diseases of the Nervous System - diagnosis
Autoimmune Diseases of the Nervous System - drug therapy
Cardiology
Case Report
Diabetes
Endocrinology
Ganglia, Autonomic - pathology
Gastroenterology
Humans
Immunologic Factors - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Neurology
Ophthalmology
Rituximab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present a patient with autoimmune autonomic ganglionopathy (AAG) who had persistently positive ganglionic nicotinic acetylcholine receptor antibody levels despite immunosuppressive therapy. Rituximab-based therapy for an incidental lymphoma was associated with prolonged symptomatic and serological control of AAG.
ISSN:0959-9851
1619-1560
DOI:10.1007/s10286-015-0299-5